AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28121288 — intervention group
Group type: COMPARATOR
Intervention: Standard generic letter from the general practice advertising the local SSS.
Number of subjects: 4384
Study 28121288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention.
Number of subjects: 4384
Study 26931302 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy protein, moderate CHO diet (40% CHO: 30% protein: 30% fat; ∼4 dairy servings)
Number of subjects: 111
Study 26931302 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy protein, high CHO diet (55% CHO: 30% protein: 15% fat; ∼4 dairy servings)
Number of subjects: 111
Study 26931302 — intervention group
Group type: COMPARATOR
Intervention: Control diet (55% CHO: 15% protein: 30% fat; ∼1 dairy serving)
Number of subjects: 111
Study 24488157 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Playtime Intervention (FPI)
Number of subjects: 70
Study 24488157 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 70
Study 22943685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mesenchymal stem cells (MSCs) [(4.9 ± 1.7) × 10(8), n = 17]
Number of subjects: 53
Study 22943685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of mononuclear stem cells (MNCs) [(5.1 ± 2.0) × 10(8), n = 16]
Number of subjects: 53
Study 22943685 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n = 20)
Number of subjects: 53
Study 18978490 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg daily for 3 weeks, then 10 mg daily for 3 weeks
Number of subjects: 26
Study 18978490 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study 17724715 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) plus HPV
Number of subjects: 28000
Study 17724715 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 28000
Study 17724715 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing with cytology-triage
Number of subjects: 28000
Study 17724715 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pap test
Number of subjects: 28000
Study 15464185 — intervention group
Group type: EXPERIMENTAL
Intervention: 2EHRZ/6HE
Number of subjects: 1355
Study 15464185 — intervention group
Group type: EXPERIMENTAL
Intervention: 2(EHRZ)3/6HE
Number of subjects: 1355
Study 15464185 — intervention group
Group type: EXPERIMENTAL
Intervention: 2EHRZ/4HR
Number of subjects: 1355
Study 15464185 — intervention group
Group type: COMPARATOR
Intervention: 6-month standard regimen
Number of subjects: 1355
Study 11588522 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrendipine (20 mg/d)
Number of subjects: 39
Study 11588522 — intervention group
Group type: EXPERIMENTAL
Intervention: trandolapril (2 mg/d)
Number of subjects: 39
Study 9682676 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cooling (chilling of the integument of their heads and thoraces for 30 min)
Number of subjects: 10
Study 9682676 — intervention group
Group type: COMPARATOR
Intervention: No cooling (control phase)
Number of subjects: 10
Study 8003306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser irradiation (9.6 J/cm2, 830 nm)
Number of subjects: 51
Study 8003306 — intervention group
Group type: COMPARATOR
Intervention: Placebo or control groups
Number of subjects: 51
Study 2574764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate 100 mg daily for 6 months
Number of subjects: 76
Study 2574764 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 76
Study 31746051 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular penis-root masturbation (PRM)
Number of subjects: 37
Study 31746051 — intervention group
Group type: COMPARATOR
Intervention: Kegel exercise (KE)
Number of subjects: 37
Study 29588137 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 mg per day)
Number of subjects: 106
Study 29588137 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 U per week)
Number of subjects: 106
Study 29588137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 28389801 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia with ropivacaine and fentanyl (Epi PCA group)
Number of subjects: 86
Study 28389801 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with fentanyl (IV PCA group)
Number of subjects: 86
Study 28389801 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA group
Number of subjects: 86
Study 28389801 — intervention group
Group type: COMPARATOR
Intervention: IV PCA group
Number of subjects: 86
Study 26268910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 26268910 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg CCX140-B
Number of subjects: 332
Study 26268910 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg CCX140-B
Number of subjects: 332
Study 24157585 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow intravenous injection of photosensitizer during the first 15 minutes of irradiation (Group A)
Number of subjects: 30
Study 24157585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fomentation before photosensitizer injection and irradiation (Group B)
Number of subjects: 30
Study 24157585 — intervention group
Group type: COMPARATOR
Intervention: Traditional injection method (Control Group C)
Number of subjects: 30
Study 21905248 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous clinical remission (CR; DAS <1.6)
Number of subjects: 145
Study 21905248 — intervention group
Group type: COMPARATOR
Intervention: Continuous high disease activity (HDA; DAS >2.4)
Number of subjects: 145
Study 21905248 — intervention group
Group type: COMPARATOR
Intervention: Low disease activity (LDA; 1.6 ≥ DAS ≤ 2.4)
Number of subjects: 145
Study 18990735 — intervention group
Group type: EXPERIMENTAL
Intervention: Disparity articles (emphasizing impact, two dimensions of disparity)
Number of subjects: 300
Study 18990735 — intervention group
Group type: EXPERIMENTAL
Intervention: Progress articles (emphasizing improvement over time)
Number of subjects: 300
Study 18990735 — intervention group
Group type: COMPARATOR
Intervention: Disparity articles
Number of subjects: 300
Study 17078211 — intervention group
Group type: EXPERIMENTAL
Intervention: B+Q (Quinapril)
Number of subjects: 63
Study 17078211 — intervention group
Group type: EXPERIMENTAL
Intervention: B+V (Valsartan)
Number of subjects: 63
Study 17078211 — intervention group
Group type: EXPERIMENTAL
Intervention: B+Q+V (Quinapril + Valsartan)
Number of subjects: 63
Study 15327612 — intervention group
Group type: EXPERIMENTAL
Intervention: Video monitoring of smear-taking at colposcopy
Number of subjects: 272
Study 11561779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etoposide (3 x 400 mg/m2)
Number of subjects: 10
Study 11561779 — intervention group
Group type: COMPARATOR
Intervention: Etoposide phosphate (equimolar amount to etoposide)
Number of subjects: 10
Study 9243169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) at a dose of 0.5 g.kg‐1 body mass
Number of subjects: 8
Study 9243169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 8
Study 9243169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT)
Number of subjects: 8
Study 9243169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) and Placebo (PLC)
Number of subjects: 8
Study 8488172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 8488172 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 306
Study 8488172 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-cysteine 200 mg 4 times daily
Number of subjects: 306
Study 8488172 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-methionine-methyl sulphonium chloride (MMSC) 500 mg 4 times daily
Number of subjects: 306
Study 3552683 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV Metoclopramide (1 mg/kg/dose X 5 doses)
Number of subjects: 26
Study 3552683 — intervention group
Group type: COMPARATOR
Intervention: Combination of Metoclopramide (same schedule) plus Nortriptyline (50 mg PO X 2 doses) plus Thiethylperazine (10 mg IV X 3 doses)
Number of subjects: 26
Study 30077178 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d algal-derived DHA
Number of subjects: 957
Study 30077178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 957
Study 30077178 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 957
Study 27477773 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-based therapy
Number of subjects: 183419
Study 25137523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot saline irrigation (HSI) at 49°C, 20 mL every 10 minutes during FESS
Number of subjects: 62
Study 25137523 — intervention group
Group type: COMPARATOR
Intervention: Room temperature saline irrigation (RTSI) at 18°C, 20 mL every 10 minutes during FESS
Number of subjects: 62
Study 25137523 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 62
Study 25137523 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (MABP)
Number of subjects: 62
Study 23869107 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylscopolamine 20 mg i.v.
Number of subjects: 57
Study 23869107 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 57
Study 20216025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging for regional anesthesia
Number of subjects: 211
Study 20216025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging for peripheral nerve blocks
Number of subjects: 211
Study 20216025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging for neuraxial anesthesia
Number of subjects: 211
Study 20216025 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound imaging
Number of subjects: 211
Study 19115656 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 ml of levobupivacaine 0.1%
Number of subjects: 110
Study 19115656 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 ml of levobupivacaine 0.1%
Number of subjects: 110
Study 19115656 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 ml of levobupivacaine 0.25%
Number of subjects: 110
Study 16329083 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-care laparoscopic cholecystectomy
Number of subjects: 100
Study 16329083 — intervention group
Group type: COMPARATOR
Intervention: Overnight-stay laparoscopic cholecystectomy
Number of subjects: 100
Study 16329083 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using HADS and PGWB
Number of subjects: 100
Study 16329083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis
Number of subjects: 100
Study 12598550 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP-containing mouthrinse
Number of subjects: 0
Study 12598550 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP-containing chewing gum
Number of subjects: 0
Study 12598550 — intervention group
Group type: COMPARATOR
Intervention: Other forms of calcium (in comparison)
Number of subjects: 0
Study 10992172 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry scan
Number of subjects: 1610
Study 8970819 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3 x 320 mg capsules every 6 h for 3 days, total 3.84 g/day)
Number of subjects: 0
Study 8970819 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical schedule as aspirin)
Number of subjects: 0
Study 1385090 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning stimulus (peripheral nerve stimulus)
Number of subjects: 16
Study 1385090 — intervention group
Group type: EXPERIMENTAL
Intervention: C-T paradigm
Number of subjects: 16
Study 2868900 — intervention group
Group type: EXPERIMENTAL
Intervention: endralazine 5 mg
Number of subjects: 22
Study 2868900 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 29748932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 or 1000 mg twice daily for 37 weeks
Number of subjects: 22
Study 29748932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin in obese adolescents
Number of subjects: 22
Study 27647769 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO) intradermal injection at 1:7 cc dilution (500 unit in 7 cc of NSS)
Number of subjects: 22
Study 27647769 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 22
Study 27647769 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO) intradermal injection
Number of subjects: 22
Study 27647769 — intervention group
Group type: EXPERIMENTAL
Intervention: Age younger than 32 receiving AbobotulinumtoxinA (ABO)
Number of subjects: 22
Study 23636866 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral dilatation (UD) plus cystoscopy
Number of subjects: 50
Study 23636866 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy alone
Number of subjects: 50
Study 22886431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment at fluences of 7 J/cm²
Number of subjects: 13
Study 22886431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment at fluences of 12 J/cm²
Number of subjects: 13
Study 22886431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment at fluences of 20 J/cm²
Number of subjects: 13
Study 22886431 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated area)
Number of subjects: 13
Study 22886431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 13
Study 20942239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial lavage (BL) with 1% lidocaine (2 ml) and 0.125% metronidazole (5 ml) during bronchoscopic procedure
Number of subjects: 123
Study 20942239 — intervention group
Group type: COMPARATOR
Intervention: Rigid bronchoscopic retrieval of foreign bodies under general anaesthesia (Control group)
Number of subjects: 123
Study 18307585 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine, Risperidone, Haloperidol
Number of subjects: 99
Study 18307585 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched healthy controls)
Number of subjects: 99
Study 18307585 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (Olanzapine, Risperidone, Haloperidol)
Number of subjects: 99
Study 16297488 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year lifestyle intervention
Number of subjects: 78
Study 16297488 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 12418584 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 194
Study 12418584 — intervention group
Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 194
Study 12418584 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with initial FEV1 in the range 30-65% predicted
Number of subjects: 194
Study 12418584 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 194
Study 12418584 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 slopes calculated using first four assessments
Number of subjects: 194
Study 12418584 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-bronchodilator values
Number of subjects: 194
Study 10435809 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy in p53 negative patients
Number of subjects: 163
Study 10435809 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy in p53 positive patients
Number of subjects: 163
Study 10435809 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between p53 status and benefit of radiotherapy
Number of subjects: 163
Study 7812552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 57
Study 2297337 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug in one eye
Number of subjects: 396
Study 2297337 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the fellow eye
Number of subjects: 396
Study 101843 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug combination (hexamethylmelamine, cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 80
Study 101843 — intervention group
Group type: COMPARATOR
Intervention: Melphalan
Number of subjects: 80
Study 101843 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with minimal residual disease
Number of subjects: 80
Study 101843 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with advanced disease achieving complete remission
Number of subjects: 80
Study 30761945 — intervention group
Group type: EXPERIMENTAL
Intervention: Move-A-Thon (MAT) event with monetized donations to charity, incentivizing participants to achieve a minimum of 3,000 daily steps for 2 weeks.
Number of subjects: 8
Study 28795638 — intervention group
Group type: EXPERIMENTAL
Intervention: Legflow paclitaxel‐eluting balloon (PEB) + Supera stenting
Number of subjects: 160
Study 28795638 — intervention group
Group type: COMPARATOR
Intervention: Supera stenting alone
Number of subjects: 160
Study 25882198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated strategies
Number of subjects: 120
Study 25882198 — intervention group
Group type: COMPARATOR
Intervention: Taught strategies
Number of subjects: 120
Study 24012453 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT plus thrombolysis
Number of subjects: 69
Study 24012453 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 69
Study 21871998 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 ischemia (G3I)
Number of subjects: 1308
Study 19463196 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-step clinical pathway implementation process
Number of subjects: 180
Study 19463196 — intervention group
Group type: COMPARATOR
Intervention: Hard copy of Australian national guidelines for chest pain and AMI management
Number of subjects: 180
Study 19153426 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 0
Study 19153426 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 0
Study 11100449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodifuse Iode system (iodine release system) used in three villages
Number of subjects: 0
Study 11100449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iodine release system) in one village
Number of subjects: 0
Study 8866933 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 (40 mg for 6 weeks)
Number of subjects: 50
Study 8866933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8866933 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 (responders)
Number of subjects: 50
Study 8866933 — intervention group
Group type: COMPARATOR
Intervention: Placebo (responders)
Number of subjects: 50
Study 1299257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Number of subjects: 694
Study 1299257 — intervention group
Group type: COMPARATOR
Intervention: Cotton roll isolation
Number of subjects: 694
Study 6509234 — intervention group
Group type: EXPERIMENTAL
Intervention: Full package of environmental changes and toilet training at peak evacuation times (Ward A)
Number of subjects: 3
Study 6509234 — intervention group
Group type: COMPARATOR
Intervention: Combination of two-hourly toileting for five weeks and environmental changes (Ward B)
Number of subjects: 3
Study 6509234 — intervention group
Group type: COMPARATOR
Intervention: Only environmental changes (Ward C)
Number of subjects: 3
Study 31664594 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise30 (30 train noise events, 52 dB(A))
Number of subjects: 70
Study 31664594 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise60 (60 train noise events, 54 dB(A))
Number of subjects: 70
Study 31664594 — intervention group
Group type: COMPARATOR
Intervention: Control (background noise, 33 dB(A))
Number of subjects: 70
Study 31664594 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise30
Number of subjects: 70
Study 31664594 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise60
Number of subjects: 70
Study 28940316 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 28940316 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0
Study 26667449 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg QD
Number of subjects: 112
Study 26667449 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg Q-MWF
Number of subjects: 112
Study 26667449 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 1.0 mg Q-MWF
Number of subjects: 112
Study 26667449 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 0.25 mg Q-MWF
Number of subjects: 112
Study 26667449 — intervention group
Group type: COMPARATOR
Intervention: Control (standard dose arm)
Number of subjects: 112
Study 26667449 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose arms
Number of subjects: 112
Study 25419767 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance cultures from nares, oropharynx, groin, perianal area, wounds, and device insertion sites
Number of subjects: 120
Study 25419767 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening extranasal sites
Number of subjects: 120
Study 25419767 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling device insertion sites, groin, and perianal area
Number of subjects: 120
Study 25419767 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-associated MRSA strains (USA100 and USA100 variants)
Number of subjects: 120
Study 22487197 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents and adults (young, middle-aged, and older) with 25(OH)D levels ≤50 nmol/L in winter/spring
Number of subjects: 2075
Study 22487197 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents and adults (young, middle-aged, and older) with 25(OH)D levels ≤25 nmol/L in winter/spring
Number of subjects: 2075
Study 22487197 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary schoolchildren with 25(OH)D levels <50 nmol/L
Number of subjects: 2075
Study 22487197 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary schoolchildren with 25(OH)D levels ≤25 nmol/L
Number of subjects: 2075